Eli Lilly's CEO frames obesity not as a single issue but as a central "nodal" point connected to over 200 other chronic diseases. This perspective highlights that effectively treating obesity can create a powerful cascading positive effect on the entire healthcare system.
Beyond weight loss, GLP-1s surprisingly curb addictive behaviors like drinking, smoking, and gambling. They work not by eliminating joy, but by reducing the pleasure derived from "one more" indulgence, effectively making people want less of these substances and activities.
Our evolutionary instincts for craving scarce resources haven't adapted to the modern world of abundance. GLP-1 drugs provide a biological support system, or "scaffolding," that helps regulate these outdated cravings for things like high-calorie food and other hedonic activities.
Eli Lilly bypassed traditional pharmacy channels with its 'Lilly Direct' program, which cut consumer prices by 60%. Counterintuitively for pharmaceuticals, they found pricing is highly elastic: the more they lower the price, the more users they acquire, which ultimately grows the business.
AI cannot yet revolutionize drug discovery because its strength is synthesizing existing knowledge. The problem is that humans only understand about 20% of the human body's biology, meaning the foundational dataset is too incomplete for AI to reliably predict outcomes for the unknown 80%.
Men, and particularly fathers and sons, often build stronger connections while engaged in a shared activity like hiking or fishing rather than through direct, face-to-face conversation. This 'side-by-side' dynamic creates a more natural and less pressured environment for communication to occur.
Scott Galloway and Eli Lilly's CEO David Ricks both contend that GLP-1 technology is currently underhyped, while AI is overhyped. They argue GLP-1s will ultimately have a more profound and transformative impact on society and health than artificial intelligence.
Eli Lilly's market dominance stems from its 2018 bet on obesity drugs, a field then considered a 'non-market.' Their philosophy is that by the time a medical market is large and obvious, it's too late to invest in R&D. They prioritize investing where the science is profound, not where the market currently is.